Hikma has struck a deal with Glenmark to gain US rights to its Ryaltris nasal spray. The agreement comes as Hikma reported sales ahead by 7% in 2019 on strong performances from the firm’s Injectables and Branded segments.
Hikma has struck a deal with Glenmark to gain US rights to the Indian firm’s investigational Ryaltris (olopatadine/mometasone) nasal spray. The agreement builds on what Hikma said was its “market-leading position in nasal allergy sprays.”
Glenmark will continue to develop the product and will be responsible for gaining US Food and Drug Administration approval, while...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
